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license (http://creativeof tauopathies. Histamine H3-receptor antagonists have been proposed to reduce tau hyperphosphor-
ylation in preclinical models.
Methods: We evaluated the ability of SAR110894, a selective histamine H3-receptor antagonist, to
inhibit tau pathology and prevent cognitive deficits in a tau transgenic mouse model (THY-Tau22).
Results: SAR110894 treatment for 6 months (but not 2 weeks) in THY-Tau22 mice decreased both
tau hyperphosphorylation at pSer396-pSer404 (AD2 signal) in the hippocampus and the number of
AT8 (pSer199/202-Thr205) positive cells in the cortex and decreased the formation of neurofibrillary
tangles in the cortex, hippocampus, and amygdala. Macrophage inflammatory protein 1-alpha
messenger RNA expression was decreased in the hippocampus. SAR110894 also prevented episodic
memory deficits, and this effect was still detected after treatment washout.
Discussion: Long-term SAR110894 treatment could have potential disease modifying activity in
neurodegenerative tauopathies.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Tau pathology; Cognition; Histamine H3-receptor; THY-Tau22; Transgenic1. Background
The histamine H3-receptor (H3R) is expressed in many
brain regions, including those involved in sleep/wake regula-
tion and cognitive functions [1]. At the presynaptic level, in-
hibition of the H3R leads to increased release of several
neurotransmitters, which induce activation of postsynaptic
signaling pathways relevant to cognitions, making this recep-
tor a potential drug target for regulating the enhancement of
arousal or cognitive processes. Extensive preclinical data
with H3R antagonists support their potential use for the treat-thor. Tel.: 133 160496194; Fax: 133 160497442.
ilippe.delay-goyet@sanofi.com
16/j.trci.2016.10.002
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).ment of human cognitive disorders, including Alzheimer’s
Disease (AD) [1]. The activation by H3R antagonists of post-
synaptic signaling pathways also relevant to neuroprotection
(such as the Akt/GSK3b pathway, which is involved in tau
phosphorylation) was recently suggested [2,3].
The microtubule-associated tau protein is abundant in
the nervous system, especially concentrated in neurons
where it regulates the assembly and stabilization of the
microtubule cytoskeleton [4]. In neurodegenerative tauopa-
thies, such as AD, hyperphosphorylation of tau leads to its
dissociation from microtubules, leading to the formation of
neurofibrillary tangles (NFTs) composed of paired helical
filaments and the progressive destabilization of the
neuronal cytoskeleton. In AD, the amount and distributionimer’s Association. This is an open access article under the CC BY-NC-ND
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severity of the disease [5,6].
A previous study has shown that a 2-week treatment with
ABT-239, a H3R antagonist, decreases tau hyperphosphoryla-
tion (AT8 site) in ventral horn spinal motoneurons and
hippocampal CA3 mossy fibers of tau ! amyloid precursor
protein mice [7]. This prompted us to investigate whether
SAR110894, a different chemical class of H3R antagonist
with higher affinity and selectivity than ABT-239 for H3R [8],
had any effect on tau pathology in THY-Tau22 transgenicmice.
THY-Tau22 transgenic mice display age-dependent tau
pathology in the brain with minor traces of human tau pro-
tein in the spinal cord. THY-Tau22 mice show hyperphos-
phorylation of tau on several AD-relevant tau epitopes,
NFT-like inclusions (Gallyas and MC1-positive) with rare
ghost tangles, and paired helical filament–like filaments, as
well as mild astrogliosis starting from the age of 3 to
6 months. These mice also display cognitive deficits from
the age of 6 months in the absence of any motor deficits [9].
SAR110894 is a potent and selective histamine receptor
antagonist at human, rat, and mouse H3R and has shown
efficacy in several animal models related to the cognitive def-
icits in AD. For example, SAR110894 prevented the occur-
rence of episodic memory deficits induced by scopolamine
in rats or by the central infusion of the toxic amyloid fragment
Ab(25–35) in the object recognition test in mice [8]. In the
present study, we evaluated the ability of SAR110894 to pre-
vent cognitive deficits and inhibit tau pathology in THY-
Tau22 mice after single, repeated, or chronic administration.2. Methods
2.1. Animals and treatment
Male THY-Tau22 transgenic and nontransgenic litter-
mates (wild-type [WT]) mice were used. In all experiments
with repeated administration, mice were housed individually
in an enriched environment. Housing was in a pathogen-free
facility at a constant temperature of 22 6 2C and humidity
(506 10%) on a reverse light/dark cycle under a 12:12 light/
dark cycle (light on at 7:00 AM) with ad libitum access to
food and water.
SAR110894 was synthesized by Sanofi medicinal chem-
istry as a difumarate salt and was given orally to the animals
in drinking water (0.002% and 0.02% for 2 weeks) or in the
diet (0.0002%, 0.002%, and 0.02% for 6 months or
0.00067% and 0.002% for 4 or 6 months). Experiments
and treatment groups are shown in Table 1. Body weights
were measured weekly. All protocols were approved by
the Ethical Committee for Animal Research of Sanofi-
Aventis. Animal facilities and animal care and use programs
were in accordance with French legislation, which imple-
mented the European directive 86/609/EEC.
The animals were homogeneously distributed in the treat-
ment groups according to their body weights and timing oftest sessions at the different open fields used in the object
recognition test.
The study investigators were not blinded to treatment
assignment. Behavioral experiments were carried out by
two different experimenters.
Further details are provided in Supplementary Material
(see Supplementary Methods).
2.2. Shape and spatial memory assessment using the
object recognition test
The test apparatus was based on that described byEnnaceur
and Delacour [15] in rats and adapted for use in mice. The
enclosure (59! 59! 30 cm)wasmade of polyvinyl chloride,
with four black walls and a white floor and a camera located
150 cm above the enclosure. The observer was located in an
adjacent room fitted with a video monitoring system. The
task procedure consists of three sessions: habituation, acquisi-
tion, and recall, all carried out between 9:00 AM and 1:15 PM.
Further details are provided in Supplementary Material
(see Supplementary Methods).
2.3. Brain tissue and blood sampling
At the completion of the experiments, blood samples
were collected from awake animals from the mandibular
vein and transferred into Sarstedt tubes containing lithium
heparin. After centrifugation (1500–2000g for 10 minutes
at 4C) plasma samples were frozen in microtubes and
stored at 280C.
Mice were sacrificed without anesthesia, as anesthesia has
been shown to increase tau hyperphosphorylation through hy-
pothermia [16], and brains removed. Hippocampi, cingulate
cortex, amygdala, and dentate gyrus or hemibrains were
dissected from each mouse using a coronal acrylic slicer
(Delta Microscopies) at 4C and stored at 280C until used
for biochemical, RNA, or pharmacokinetics (PK) analyses.
The second hemibrains (to be used in histopathologic studies)
were immersion-postfixed for 7 days at 4C with 4% formal-
dehyde (Carlo Erba/code 415691).
2.4. Quantification of SAR110894 levels in blood and
brain samples
For both plasma and brain tissue samples, after addition of
the precipitant solution (acetonitrile), SAR110894 was quanti-
fied by liquid chromatography-mass spectrometry/mass spec-
trometry. Deuterium-labeled SAR110894 (D5-SAR110894)
was used as an internal standard.
Further details are provided in Supplementary Material
(see Supplementary Methods).
2.5. Histology and immunohistochemistry
Postfixed hemibrains were cryoprotected in 20% sucrose
solution (for 48 hours at 4C) before subsequent rapid
freezing in isopentane. Serial sagittal cryostat tissue sections
Table 1
Doses and treatment duration used in the different experiments
Experiment (repeated administration) Genotype
Age at beginning of
treatment (mo) Treatment Number
2 wk in drinking water THY-Tau22 5–6 Vehicle 9
AD2, AT8, Ser9-GSK3b signals (Western blot) 0.002% 9
0.02% 9
6 mo in food WT 2 Vehicle 16
Object recognition (during treatment) 0.0002% 15
AD2, AT8, pSer214-, pSer262-, pSer422-, and pThr181-tau
signals (Western blot)
0.002% 15
0.02% 15
AT8 immunostaining THY-Tau22 Vehicle 17
NFTs (Gallyas silver staining) 0.0002% 17
MIP-1a, cystatin F, GFAP mRNA 0.002% 17
0.02% 17
4 mo (12 mo of treatment washout) or 6 mo in food WT 2.5 Vehicle 15
Without or with treatment cessation 0.00067% 15
0.002% 15
Pharmacokinetics THY-Tau22 Vehicle 20
Object recognition test 0.00067% 20
Shape object recognition testing: 10 d after treatment cessation 0.002% 20
Spatial object recognition testing: 17 d after treatment cessation 0.002% 1 treatment cessation 20
Abbreviations: GFAP, glial fibrillary acidic protein; MIP-1a, macrophage inflammatory protein 1-alpha; mRNA, messenger RNA; NFTs, neurofibrillary
tangles; PK, pharmacokinetics; WT, wild-type.
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scope glass slides (VWR, Radnor, PA) and then stored at
220C or placed in phosphate-buffered saline–sodium azide
0.1% (S-2002, Sigma) containing wells to avoid any
contamination and stored at 4C.
Further details are provided in Supplementary Material
(see Supplementary Methods).2.6. Quantitative image analysis of Gallyas staining and
AT8 immunostaining
Gallyas staining and AT8 immunostaining were quantita-
tively determined using microscopic virtual slide technology
using an Olympus dotslide scanner system and a computer-
based workstation (Explora Nova using Mercator software)
[17-19].
Further details are provided in Supplementary Material
(see Supplementary Methods).2.7. Western blot analysis of tau phosphorylation in cortex
and hippocampus homogenates
For immunoblot analysis, frozen mouse tissues (hippo-
campus or cortex) were homogenized using a Precellys 24 tis-
sue homogenizer in 350 mL radioimmunoprecipitation assay
buffer from Cell Signaling (20 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1 mM Na2 ethylene diamine tetraacetic
acid, 1 mM ethylene glycol tetraacetic acid, 1% 4-
nonylphenylpoly(ethylene glycol), 1% sodium deoxycholate,
2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate,
1 mMNa3VO4, and 1 mg/mL leupeptin) to which protease in-
hibitors (Sigma cocktail 1% vol/vol) and phosphatase inhibi-
tors (okadaic acid 1 mM and sodium fluoride 100 mM) were
added. After centrifugation, 16,000g at 4C for 10 minutes,the protein content in supernatants was determined with a
BioRad DC Protein Assay kit, using bovine serum albumin
as a standard. Equal amounts of protein (5 or 20 mg) were
loaded on 15-well 4% to 12% Bis-Tris gels (NuPAGE; Invi-
trogen) and electrophoresis was performed at 200V for 50mi-
nutes in 3-(N-morpholino)propanesulfonic acid buffer,
according to the manufacturer’s instructions. Proteins were
then transferred to polyvinylidene difluoride membranes
(Invitrogen; Thermo Fisher Scientific Corporation, Waltham,
MA) at 30 V for 2 hours in transfer buffer (Invitrogen) con-
taining 20% methanol. After blocking in 5% nonfat dry
milk in tris-buffered saline Tween 0.1%, blots were incubated
overnight at 4C with primary antibodies diluted in 5%
bovine serum albumin in tris-buffered saline Tween 0.1%.
Further details are provided in Supplementary Material
(see Supplementary Methods).2.8. Messenger RNA extraction and quantitative real-time
reverse transcription polymerase chain reaction analysis
A hemihippocampus from each mouse was placed in a
Precellys CK14 tube including 50 ceramic beads (1.4 mm
diameter) and 0.5 mL of Applied Biosystems’ nucleic acid
purification lysis solution (1!). The tissue was homoge-
nized using a homogenizer Precellys 24 (Bertin Technology)
during 2! 10 seconds bursts. Total RNAwas isolated using
the 6100 PrepStation (Applied Biosystems), according to the
manufacturer’s instructions, including a DNase treatment
(protocol isolation of total RNA from plant and animal tis-
sue). To assess the quality and concentration of the total
RNA, 1 mL was analyzed on a RNA LabChip (Agilent Tech-
nologies) using a 2100 Bioanalyzer (Agilent Technologies).
Further details are provided in Supplementary Material
(see Supplementary Methods).
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Results are expressed as the means 6 standard error of
the mean (SEM) or means 6 standard deviation. Statistical
analyses were performed using SAS system release 9.2 for
HP-UX via Everstat 6.0 internal software. All data sets
passed the Kolmogorov-Smirnov test for normality and Lev-
ene test for variance homogeneity.
Depending on the data obtained, each treated group was
compared with a control group with a two-sided Dunnett
test or a two-sidedWilcoxon test with Bonferroni-Holm mul-SAR110894 0.00067%
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Fig. 1. Time course of total SAR110894 concentrations in plasma and pons/cerebell
(B) SAR110894 in diet to male wild-type mice. Results are expressed as the meantiplicity correction. For two-group comparison, the two-sided
Student t test or two-sided Wilcoxon test was used.3. Results
3.1. Plasma and brain exposure of SAR110894 in WTmice
The PK parameters for SAR110894 were measured in
male WT mice after a 5-month repeated oral administration
of SAR110894 (0.00067% or 0.002% in diet). SAR110894
concentrations were measured in the plasma and pons/Time (hour)
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um after a 5-month repeated oral administration of 0.00067% (A) and 0.002%
1standard deviation. n 5 3 per group. LLOQ, lower limit of quantitation.
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erate interanimal variability. The concentrations in both
plasma and brain were roughly constant over the period of
sampling collection (i.e., 24 hours; Fig. 1A and B) with
Cmax/Cmin ratios ranging from 1.4 to 2.7 (Table 2). Both
the Cmax and the area under curve (AUC)(0–24 h) in plasma
and brain increased in a dose proportional manner (Cmax
from 6.63 to 24.8 nM and from 20.7 to 91.6 nM, respec-
tively; AUC(0–24 h) from 31 to 110 ng h/mL and from 110
to 390 ng h/g, respectively; Table 2). The SAR110894
“brain/plasma” exposure ratio was 3.5 at both doses demon-
strating good brain penetration of the compound.
Taking into account the exposure in the plasma after a sin-
gle oral administration (data not shown), 0.002%
SAR110894 in the diet was calculated to be bioequivalent
to a 1 mg/kg single oral dose. This dose has been shown to
be active in a variety of animal models [8].3.2. Chronic treatment with SAR110894 reduced cognitive
deficits in THY-Tau22 mice
THY-Tau22 mice have been reported to have impaired
spatial learning, social recognition memory, and appetitive
learning (but not to have any impairment in passive avoidance,
fear learning, or extinction learning), with the first signs of
cognitive impairment arising by the age of 7 to 8 months
[20]. We used the object recognition test because we observed
cognitive impairment in shape memory as soon as 5.5 months
(internal data not published) and both the shape and spatial test
designs were applied because they are dependent on cortical
[21–27] and hippocampal [28,29] functions, respectively.
Fig. 2 shows that 6- to 7-month-old THY-Tau22 mice dis-
played an impairment of shape (panels A and C) and spatial
(panels B and D) episodic memory compared with age-
matched WT mice in the object recognition test.
SAR110894 administered during 4 or 6 months starting at
the age of 2 months prevented cognitive deficits in THY-
Tau22 mice (Fig. 2). SAR110894 (0.002% and 0.02%)
reduced the deficits in both shape episodic memory (recog-
nition index [means 6 SEM]: 64 6 2%, P 5 .0010 and
61 6 3%, P 5 .0104, respectively; Fig. 2A) and spatial
episodic memory (recognition index [means 6 SEM]:
586 3%, P5 .0153 and 606 2%, P5 .0002, respectively;
Fig. 2B). PK parameters of SAR110894 at the three doses
tested were measured (Supplementary Table 2).
In an independent confirmatory study, 4 months of treat-
ment with a lower dose of SAR110894 (0.00067%) reduced
the deficit in spatial episodic memory (Fig. 2D) but had no
effect on the deficit in shape episodic memory (Fig. 2C).
The procognitive effect of SAR110894 (0.002%) on
shape episodic memory (Fig. 2C) and spatial episodic mem-
ory (Fig. 2D) still persisted after 1 or 2 weeks of treatment
washout, respectively. After 1 week of washout, the concen-
trations of SAR110894 were less than the level of quantifica-
tion in both the plasma and pons/cerebellum (Supplementary
Table 3).
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Fig. 2. Chronic 4-month oral treatment with SAR110894 starting at the age of 2 months prevented shape (A, C) and spatial (B, D) object recognition deficits in
6- to 6.5-month-old (A, B) (first experiment) or 6.5- to 7-month-old (C, D) (second experiment) THY-Tau22 mice. The procognitive effect of SAR110894 on
shape (C) and spatial (D) memory still persisted after 1 or 2 weeks of treatment washout, respectively. Results are expressed as the mean recognition index
(%) 1 standard error of the mean. #P , .001 versus WT vehicle (Student t test (A) and Wilcoxon test (B–D)), *P , .05, **P , .01, ***P  .001 versus
THY-Tau22 vehicle (Dunnett test (A) or Wilcoxon test with Bonferroni-Holm correction (B–D)), n5 10 to 13 mice per group (A, B) or 7 to 11 mice per group
(C, D). WT, wild-type; Veh, vehicle. Doses of SAR110894 (SAR) are expressed in percents. Dotted line corresponds to chance level.
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SAR110894 on tau pathology in THY-Tau22 mice
3.3.1. Tau phosphorylation
Acute administration of SAR110894 (3 and 10 mg/kg
orally) had no effect on tau hyperphosphorylation (AD2 or
AT8 epitopes) in the cingulate cortex of 3-month-old
THY-Tau22 mice (data not shown). PK parameters of
SAR110894 (10 mg/kg orally) were measured
(Supplementary Table 1).
Moreover, a subacute 2-week treatment with SAR110894
(0.002% and 0.02% in drinking water, bioequivalent to sin-
gle oral doses of 1 and 10 mg/kg) also had no effect on tau
hyperphosphorylation (AD2 or AT8) in the hippocampus
of 5- to 6-month-old THY-Tau22 mice (Fig. 3A and B) or
on the level of Ser9-GSK3b (inactive form of GSK3b;
Fig. 3C).
To determine if longer treatment with SAR110894
was needed to observe an effect on tau pathology,THY-Tau22 mice were treated with SAR110894 for
6 months starting at the age of 2 months (the same ani-
mals were used for cognition readouts, see Section
3.2). Using this chronic treatment protocol, SAR110894
(0.002%) significantly decreased (237%, P 5 .0291)
tau phosphorylation at residues 396/404 (AD2 signal)
measured by immunoblot in the hippocampus (Fig. 4A)
and showed a trend to decrease (257%, P 5 .2766) the
AD2 signal in the cortex (Fig. 4B).
In a second independentWestern blot evaluation in cortex
homogenates comparing “vehicle group” and the dose of
“0.002%,” the inhibition of AD2 signal in the cortex on treat-
ment was confirmed and significant (237%, P 5 .0191;
Fig. 4F). SAR110894 (0.002%) also significantly decreased
tau phosphorylation at pSer214 (235%, P 5 .0052) in the
cortex but had no effect on tau phosphorylation at pThr181
(AT270 signal; 216%, P 5 .4830) and pSer422 (220%,
P 5 .3019). Total tau (Tau5 signal) was unchanged
(217%, P 5 .0950).
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Fig. 3. Two-week oral treatment of 5- to 6-month-old THY-Tau22 mice
with SAR110894 had no effect on tau hyperphosphorylation or Ser-9
GSK3b phosphorylation in the hippocampus. (A) Tau hyperphosphoryla-
tion on AD2 epitope, (B) tau hyperphosphorylation on AT8 epitope, and
(C) Ser-9 phosphorylation. Western blot quantifications are expressed as
relative values and represented as the means 1standard error of the mean
(Dunnett tests (A, C) or Wilcoxon tests with Bonferroni-Holm correction
(B)), n 5 9 mice per group. Veh, vehicle. Doses of SAR110894 (SAR)
are expressed in percents.
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tau phosphorylation at residues Ser199/202-Thr205 (AT8
signal) in the hippocampus (222%, P 5 .5560; Fig. 4D)
or in the cortex (229%, P 5 .8054; Fig. 4E).
Akt, pAkt(Ser473), pAkt(Thr308), ERK1,
pERK1(Thr202/Tyr204), ERK2, pERK2(Thr185/Tyr187),
and demethylated PP2A levels were not changed by
SAR110894 (0.002%) treatment (Western blot evaluation,
see Supplementary Table 4).The effect of a 6-month treatment with SAR110894 on
tau phosphorylation was further evaluated by immunohisto-
chemistry, a technique more sensitive than Western blot
analysis when the antigen is heterogeneously distributed.
As illustrated in Fig. 5, the pathological process of abnormal
tau hyperphosphorylation in neurons was reduced after
SAR1100894 treatment. Within the cortex, the number of
AT8-positive neuronal cell bodies was significantly
decreased by 47% (P 5 .0010) and 32% (P 5 .0250) after
treatment with SAR110894 (0.002% and 0.02%, respec-
tively; Fig. 5C). In addition, a marked decrease in the inten-
sity of AT8 immunostaining was observed within the
neuronal cell bodies and fibers in the cortex of mice treated
with SAR110894 (0.002%; data not shown). No significant
decrease in AT8-positive neuronal cell number was detected
in other brain regions (i.e., the amygdala and both CA1 and
dentate gyrus hippocampal subareas; data not shown).
3.3.2. Neurofibrillary tangles
The effect of SAR110894 on tau pathology was further
evaluated by measuring NFTs using the Gallyas silver
impregnation staining. Abnormal tau protein aggregation
was reduced after 6 months of SAR110894 treatment in
THY-Tau22 transgenic mice, as shown in Fig. 6. The number
of NFTs in the cortex was significantly decreased by248%
(P5 .0001) and241% (P5 .0019), at SAR110894 0.002%
and 0.02%, respectively (Fig. 7A). SAR110894 also signif-
icantly decreased the number of NFTs in the hippocampus
(225%, [P , .0001] and 222% [P 5 .0006]) at the doses
of 0.002% and 0.02%, respectively (Fig. 7B) and in the
amygdala (231% [P 5 .0065]) at 0.02% (Fig. 7C).3.4. SAR110894 treatment decreased hippocampal
neuroinflammation in THY-Tau22 mice
A previous study has shown that, in addition to devel-
oping tau pathology, THY-Tau22 mice display a mild as-
trogliosis in the hippocampus [9]. Increased expression of
glial fibrillary acidic protein (GFAP; marker of astroglio-
sis) was indeed observed in the hippocampus in our study,
together with an increased expression of macrophage
inflammatory protein 1-alpha (MIP-1a; a marker of mi-
crogliosis) and cystatin F (a marker of microgliosis ex-
pressed during demyelination [30]). After 6 months of
treatment, SAR110894 significantly decreased the expres-
sion of MIP-1a by 235% (P 5 .0087) and 236%
(P 5 .0184) at the doses of 0.0002 and 0.002%, respec-
tively (Fig. 8A). SAR110894 had no effect on the expres-
sion of GFAP or cystatin F in the hippocampus (Fig. 8B
and C, respectively).4. Discussion
In the present study, we examined the effect of
SAR110894, a selective and potent H3R antagonist [8], on
cognitive deficits, tau hyperphosphorylation, and the
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Fig. 4. Chronic oral treatment with SAR110894 during 6 months starting at 2 months in THY-Tau22 mice decreased tau hyperphosphorylation on AD2
(pSer396-pSer404) (A, B, C, F) and Tau pSer214 (F) but not on AT8 (D–F), AT270 (Thr181) (F), or Tau pSer422 (F) epitopes in the hippocampus (A, C,
D) and cortex (B, C, E, F). (C) Representative Western blots with AD2 antibody in wild-type and THY-Tau22 mice showing murine endogenous tau (around
50 kDa) and human transgenic tau 4R1N (around 60 kDa). (F) Quantitation and representative Western blots with all phosphorylation-dependent antibodies
tested at the dose of SAR 0.002% (AD2, AT8, Tau pSer214, AT270, and Tau pSer422) or phosphorylation-independent (Tau5). Western blot quantifications
are expressed as the relative means 1 standard error of the mean (A, B, D, E) or expressed as individual data and relative means 6 standard error of the
mean (F). *P, .05, **P, .01 versus THY-Tau22 Vehicle (Dunnett tests (A), Wilcoxon tests with Bonferroni-Holm correction (B, D, E, F [AT8 only]) or Stu-
dent t test (F [AD2, Tau pSer214, AT270, Tau pSer422, and Tau5])), n5 8 to 9 mice per group (A, B, D, E) or 7 to 9 mice per group (F). Veh, vehicle. Doses of
SAR110894 (SAR) are expressed in percents.
P. Delay-Goyet et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 267-280274formation of NFTs in THY-Tau22 mice, a tau transgenic
mouse model. SAR110894 has been tested using different
routes of administration (gavage, drinking water, and incor-
poration in food) to fully evaluate its pharmacological activ-
ity using different experimental protocols. THY-Tau22 mice
selectively overexpress human 4-repeat tau in the brain and
display age-dependent tau pathology [9]. These mice also
exhibit behavioral and memory deficits in a broad varietyof experimental paradigms. For example, THY-Tau22 mice
display spatial reference memory deficits in a Y-maze test
at the age of 8 to 13 months [10,13,31] and in the Morris
Water maze at the age of 7 to 12 months [11,12,14,20,31].
They also show impaired social recognition memory and
appetitive learning deficits at the age of 9 to 10 months
[20]. Our data provide the first demonstration that THY-
Tau22 mice also have deficits in shape and spatial episodic
Fig. 4. (continued).
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6 months.
Previous studies have indicated that the age-dependent
cognitive impairment in THY-Tau22 mice is closely corre-
lated with the development of tau pathology in the hippo-
campus [9,31,32] and impaired brain-derived neurotrophic
factor-dependent hippocampal synaptic transmission [11].
Moreover, the potentiation of spatial learning deficits
induced by early and progressive obesity in THY-Tau22
mice is accompanied by a worsening of hippocampal tau pa-
thology [12]. Finally, pharmacological intervention with
chronic caffeine intake induced a decrease in tau hyperphos-
phorylation and proinflammatory and oxidative stress
makers in the hippocampus of THY-Tau22 mice that was
correlated with a reduction in cognitive impairment [14].
We previously showed that acute treatment with
SAR110894 has procognitive activity in several animalmodels
displaying cognitive deficits relevant to those found in patients
with AD [8]. For example, in the object recognition test
SAR110894 prevented the occurrence of scopolamine-
inducedmemory deficits in rats and decreased thememory def-
icits induced by infusion of Ab(25–35) in mice. SAR110894
also decreased memory deficits observed in the same behav-
ioral test in APPxPS1 transgenic mice (data not shown).
The acute procognitive activity of SAR110894 in THY-
Tau22 mice is consistent with a symptomatic effect related
to the increased release of several neurotransmitters, such
as histamine and acetylcholine, induced by inhibition ofthe H3R, that have been implicated in the regulation of
arousal and cognitive processes [1] because in our study
acute treatment with SAR110894 had no effect on tau hyper-
phosphorylation. In contrast, the improvement in cognitive
function after chronic treatment with SAR110894, which
was maintained after treatment washout, was correlated
with a significant decrease in tau hyperphosphorylation, a
reduction in the number of NFTs, and the decreased expres-
sion of MIP-1a (a marker of microgliosis and recently pro-
posed to play a role in synaptic plasticity mechanisms
involved in learning and memory functions [33]), suggesting
a potential disease modifying effect.
Our finding that chronic, but not acute, treatment with
SAR110894 decreases tau pathology in THY-Tau22 mice
is different from previously published data obtained with
another H3R antagonist, ABT-239, which has been shown
to decrease tau hyperphosphorylation (AT8-positive cells)
in the spinal cord and hippocampus of tau ! amyloid
precursor protein AD-transgenic mice after 2 weeks of treat-
ment [7]. The reason for these different findings is unclear,
but could be because of the different animal models used
or to differences in the techniques used tomeasure tau hyper-
phosphorylation (i.e., immunohistochemistry vs. Western
blot). These technical differences could also account for
the different effect of SAR110894 and ABT239 on the activ-
ity of GSK3b because ABT-239 increased the levels of
pSer9-GSK3b (inactive form of GSK3b) in the cortex of
CD1 mice and reversed the reduction in hippocampal
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Fig. 5. Chronic oral treatment with SAR110894 during 6 months starting at 2 months decreased the number of AT8-positive cells in the cortex of 8-month-old
THY-Tau22 mice. (A) Illustrative images of tau pathology detected by AT8 immunostaining in a representative vehicle-treated animal. Large image in (A) cor-
responds to sagittal section within medial part of the hemibrain. Delimited subarea (B) over image (A) indicates cortical subarea. B0 and B00 inserts (with higher
magnification view): SAR110894 decreases tau hyperphosphorylation in the cortical area of an SAR110894 0.002%-treated animal (B00) versus a vehicle-treated
animal (B0). Scale bar5 1 mm (A) or 100 mm (B0, B00). (C) Quantification of decrease in number of AT8-positive cells. AT8 immunostaining is expressed as the
mean positive cell bodies count1 standard error of the mean. *P, .05, ***P .001, versus THY-Tau22 vehicle (Dunnett tests on log-transformed data). n5 9
mice per group. Veh, vehicle. Doses of SAR110894 (SAR) are expressed in percents.
P. Delay-Goyet et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 267-280276pSer9-GSK3b levels in Tg2576 (APP) AD-transgenic mice,
whereas SAR110894 had no effect on pSer9-GSK3b levels
in THY-Tau22 mice.
The fact that SAR110894 has no effect on the level of
GSK3b activation and several other kinases implicated intau phosphorylation, nor it has similar effects on tau phos-
phorylation from one brain area to another and it does not
show clear dose dependencies, suggests that the inhibition
of tau pathology after chronic treatment with SAR110894
is not mediated by a direct inhibition of a tau kinase. The
Fig. 6. Chronic oral treatment with SAR110894 during 6months starting at 2months decreases the number of neurofibrillary tangles in the cortex. Illustration of
tau pathology detected by Gallyas staining in vehicle-treated animals (A, B) corresponds to sagittal sections in the lateral and medial parts of the hemibrain,
respectively. Subarea images in (A) and (B) indicate three brain areas with marked tau pathology at the age of 8 months: amygdala (C), cortex (D), and hip-
pocampus (E). (C0–E00) Different inserts (with higher magnification) demonstrate decrease in neurofibrillary tangles induced by SAR110894 in the amygdala (C0
and C00), cortex (D0 and D00), and hippocampus (E0 and E00) of an SAR110894 0.002%-treated animal (C00, D00, E00) versus a vehicle-treated animal (C0, D0, E0).
Scale bar 5 1 mm (A, B) or 100 mm (C0–E00).
P. Delay-Goyet et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 267-280 277inhibition of tau pathology by SAR110894 could therefore
be mediated by an inhibition of a Gai/o-coupled H3R-
regulated intracellular kinases (e.g., ERK1/2, PI3K/Akt,
GSK3b, and PKA), which are known to induce tau phos-
phorylation [2,3]. Moreover, SAR110894 decreases the
hyperphosphorylation of tau epitopes that are known to be
phosphorylated by H3R-regulated kinases: pSer-214, phos-
phorylated by PKA; pSer396-pSer404, phosphorylated by
GSK3b and ERK1/2. However, at the dose of 0.002%, we
did not detect any significant change of the expression and
phosphorylation state of different kinases (Akt and Erk1/2)
measured by Western blot in cortex. It is also unlikely that
inhibition of phosphorylation at any single tau epitope can
explain the significant decrease in the number of NFTsobserved with SAR110894. In addition, an indirect effect
could be mediated by a long-term activation of postsynaptic
receptors by evoked release of neurotransmitters, such as
histamine, dopamine, and acetylcholine. By its effect on
arousal and increased perception of environmental stimuli,
SAR110894 could also mimic the effect reported by com-
plex environment experience on the reduction in levels of
hyperphosphorylated tau in APPswe/PS1DE9 transgenic
mice, another model of AD [34].
Over the past years, numerous H3R antagonists have been
developed in the clinic for cognitive disorders, including AD,
but none reached the late development stage [35–39]. In short,
duration trials (4–24 weeks) aimed at demonstrating a
symptomatic effect on cognition in patients with mild or
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Fig. 7. Quantification of decrease in Gallyas staining in the cortex (A), the
hippocampus (B), and the amygdala (C) of 8-month-old THY-Tau22 mice
after chronic oral treatment with SAR110894 during 6 months starting at
2 months. Results are expressed as the mean positive cell
count 1 standard error of the mean. **P , .01, ***P , .001 versus
THY-Tau22 vehicle (Dunnett tests [on log-transformed data in panel A]).
n 5 9 mice per group. Veh, vehicle. Doses of SAR110894 (SAR) are ex-
pressed in percents.
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Fig. 8. Chronic oral treatment with SAR110894 during 6 months starting at
2 months reduced the expression of MIP-1a (A), a marker of microgliosis in
the hippocampus of 8-month-old THY-Tau22 mice. GFAP (B) and cystatin
(C) levels were not modified by the treatment. qPCR quantifications are ex-
pressed as the means 1standard error of the mean. #P , .01 versus WT
vehicle (Wilcoxon), *P , .05, **P , .01 versus THY-Tau22 vehicle (Wil-
coxon tests with Bonferroni-Holm correction). n 5 7 to 8 mice per group.
MIP-1a, macrophage inflammatory protein 1-alpha; mRNA, messenger
RNA; RQ, respiratory quotient; Veh, vehicle; WT, wild-type. Doses of
SAR110894 (SAR) are expressed in percents.
P. Delay-Goyet et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 267-280278moderate AD, no real and sustained evidence of efficacy was
demonstrated despite robust preclinical procognitive profile.
The reporting of dose-dependent sleep disturbances was
frequent across trials. The effects occurred generally early
in treatment and varied in intensity and duration. Although
the H3R antagonists notably differ in their PK parameters
and safety profile, they are reported as safe and generally
well tolerated. Only long duration trials would allow assess-
ing whether these molecules have anti-tau/disease-
modifying properties.In conclusion, we showed that chronic administration of
SAR110894 in a transgenic mouse model of tauopathy pre-
vents cognitive deficits and inhibits tau pathology. These
data suggest that H3R antagonists could have disease-
modifying activity in patients with tauopathies.
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1. Systematic review: We reviewed PubMed literature
sources. Only one study has reported that a histamine
H3-receptor antagonist inhibits tau phosphorylation in
a transgenicmousemodel ofAlzheimer’sDisease.Data
on the other main hallmark of tauopathies, neurofibril-
lary tangles, and the demonstration of a possible func-
tional benefit have not been previously shown.
2. Interpretation: Our findings provide evidence that
chronic treatment with a new H3-receptor antagonist
in a preclinical model of tauopathy reduces the for-
mation of neurofibrillary tangles and microgliosis,
in addition to the already reported reduction in tau
hyperphosphorylation, and these effects are accom-
panied by prevention of cognitive impairment, sug-
gesting a potential disease modifying activity.
3. Future directions: The article suggests that chronic
treatment with H3-receptor antagonists could be
beneficial in tauopathies. The article also provides
an interest to conduct additional investigations to
confirm this potential therapeutic use.References
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